Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Serum neurofilament light as a biomarker in progressive multiple sclerosis

Research output: Contribution to journalReviewpeer-review

  1. Effect of Adrenomedullin on Migraine-like Attacks in Patients With Migraine: A Randomized Crossover Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. 7T Epilepsy Task Force Consensus Recommendations on the Use of 7T MRI in Clinical Practice

    Research output: Contribution to journalReviewpeer-review

  3. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Time trends in incidence, comorbidity, and mortality of ischemic stroke in Denmark, 1996-2016

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Clinical characterization of delayed alcohol-induced headache: A study of 1,108 participants

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Biomarkers of inflammation and epithelial barrier function in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Raju Kapoor
  • Kathryn E Smith
  • Mark Allegretta
  • Douglas L Arnold
  • William Carroll
  • Manuel Comabella
  • Roberto Furlan
  • Christopher Harp
  • Jens Kuhle
  • David Leppert
  • Tatiana Plavina
  • Finn Sellebjerg
  • Caroline Sincock
  • Charlotte E Teunissen
  • Ilir Topalli
  • Florian von Raison
  • Elizabeth Walker
  • Robert J Fox
View graph of relations

There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes revealed in early phase trials. In January 2019, the International Progressive MS Alliance convened a standing expert panel to consider potential tissue fluid biomarkers in MS in general and in progressive MS specifically. The panel focused their attention on neurofilament light chain (NfL) in serum or plasma, examining data from both relapsing and progressive MS. Here, we report the initial conclusions of the panel and its recommendations for further research. Serum NfL (sNfL) is a plausible marker of neurodegeneration that can be measured accurately, sensitively, and reproducibly, but standard procedures for sample processing and analysis should be established. Findings from relapsing and progressive cohorts concur and indicate that sNfL concentrations correlate with imaging and disability measures, predict the future course of the disease, and can predict response to treatment. Importantly, disease activity from active inflammation (i.e., new T2 and gadolinium-enhancing lesions) is a large contributor to sNfL, so teasing apart disease activity from the disease progression that drives insidious disability progression in progressive MS will be challenging. More data are required on the effects of age and comorbidities, as well as the relative contributions of inflammatory activity and other disease processes. The International Progressive MS Alliance is well positioned to advance these initiatives by connecting and supporting relevant stakeholders in progressive MS.

Original languageEnglish
JournalNeurology
Volume95
Issue number10
Pages (from-to)436-444
Number of pages9
ISSN0028-3878
DOIs
Publication statusPublished - 8 Sep 2020

    Research areas

  • Biomarkers/blood, Humans, Multiple Sclerosis, Chronic Progressive/blood, Neurofilament Proteins/blood

ID: 61517003